~~<i id='E14EDBB3BD'><strike id='E14EDBB3BD'><tt id='E14EDBB3BD'><pre id='E14EDBB3BD'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：hotspot 2025-09-28 07:29:50 Page View：5

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial
Next article： Bright Health sells Medicare Advantage business to Molina

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

Ozempic cut risk of death in diabetes patients with chronic kidney disease

SEBASTIENBOZON/AFPviaGettyImagesNovoNordisk’sOzempiccuttheriskofdeathinatrialofpatientswithtype2diab

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

STAT Readout Newsletter: Today in biotech, life science news

AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo